Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 167, Issue -, Pages 78-88Publisher
ELSEVIER
DOI: 10.1016/j.addr.2020.06.003
Keywords
Lymph node; Lymphatic delivery; Lipid-based nanocarrier; Lipid nanoparticle; Microfluidic device; Cancer immunotherapy
Categories
Funding
- JSPS KAKENHI [17H03974]
- Special Education and Research Expenses from the Ministry of Education, Culture, Sports, Science and Technology
- Grants-in-Aid for Scientific Research [17H03974] Funding Source: KAKEN
Ask authors/readers for more resources
It is generally known that the lymph nodes (LNs) are important tissues in cancer immunotherapy. Therefore, delivering immune functional compounds to LNs is a useful strategy for enhancing cancer immunotherapy. Lipid-based nanocarriers have been widely used as delivery systems that target LNs, but lipid nanoparticle (LNP) technology has recently attracted increased interest. High levels of nucleic acids can be efficiently loaded in LNPs, they can be used to actively deliver nucleic acids into the cytoplasm, and they can be produced on an industrial scale. The use of microfluidic devices has been particularly valuable for producing small-sized LNPs, thus paving the way for successful LN targeting. In the review, we focus on the potential of LNP technology for targeting LNs. (C) 2020 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available